Medicus Pharma (MDCX) vs Theriva Biologics (TOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Theriva Biologics (TOVX) has outperformed Medicus Pharma (MDCX) over the past year, losing 55.7% versus a loss of 96.3%. Theriva Biologics is the larger company by market cap ($10.0 million vs $138,068), about 72.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDCX | TOVX |
|---|---|---|
| Share price | $0.0921 | $0.217 |
| Market cap | $138.07K | $9.96M |
| 1-day change | -9.62% | -4.45% |
| YTD return | -93.98% | +3.33% |
| 1-year return | -96.33% | -55.71% |
| 5-year return | — | -99.80% |
| P/E ratio (TTM) | — | 0.31 |
| EPS (TTM) | $-119.00 | $0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $139.00 | $0.86 |
| 52-week low | $0.084 | $0.16 |
| Distance from 52-week high | -99.93% | -74.77% |
| Analyst consensus | none | none |
| Avg. price target upside | +4785.99% | +1052.07% |
| Average volume | 92.96K | 525.96K |
| Shares outstanding | 1.50M | 45.89M |
| Employees | 16 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Theriva Biologics is about 72.1 times larger than Medicus Pharma by market value ($9.96M vs $138.07K).
- TOVX has outperformed MDCX by 40.6 percentage points over the past year.
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
MDCX vs TOVX FAQ
Which is bigger, Medicus Pharma or Theriva Biologics?
Theriva Biologics (TOVX) is larger, with a market capitalization of $9.96M compared with $138.07K for Medicus Pharma (MDCX).
Which stock has performed better over the past year, MDCX or TOVX?
TOVX returned -55.71% over the past 12 months, compared with -96.33% for MDCX (price return, excluding dividends). Past performance does not predict future results.
Are Medicus Pharma and Theriva Biologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.